

**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/TG/2025-26/08

April 10, 2025

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - Biocon</b>

Dear Sir/Madam,

**Subject: Notification to Stock Exchanges.**

This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received approval for its ANDA for Everolimus Tablets from the US FDA, in strengths of 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg. Everolimus is a prescription medication that is indicated for the prophylaxis of organ rejection in adult patients, and in kidney and liver transplantation.

The approval will further strengthen Biocon's portfolio of vertically integrated, complex drug products.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary and Compliance Officer**  
**Membership No.: ACS 18776**